Oslo, February 7, 2019 The recent Proof of Mechanism shown for Vacc-CRX demonstrates the dynamic properties of this product obstructing both of the well-known virus entry mechanisms CCR5 and CXCR4 in a way that prevents the virus from evading the blockage through escape mutations. The product Vacc-CRX constitutes the 3rd of the three cornerstones of …
Oslo, January 23, 2019. Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, Vacc-CRX. This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors and facilitate virus neutralization. Lead optimization and drug characterization with Proof of Principle will be established within the next 6 – …
Oslo, January 10, 2019 The acquisition is in the form of an exchange of patents and rights between Bionor and Immunor AS. During Bionor’s equity raise in December 2017, Bionor pledged to dispose of all its non-HIV activities. These activities have now been transferred to Immunor through a mutual assignment agreement where Immunor acquires all …